Clinical Trial

A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

Study acronym: FRONTIER
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-07-31 -> 2026-10-31 2026-06-24
minor Completion pushed: 2027-01-31 -> 2027-04-30 2026-06-24
Trial Details
NCT Number NCT05303467
Lead Sponsor Boston Scientific Corporation
Conditions Glioblastoma Multiforme, Recurrent Glioblastoma
Enrollment 36 participants
Start Date 2022-07-30
Primary Completion 2026-10-31 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-31